ROMA - CPH-I
FDA recommended the use of the ROMA in clinical practice to help stratify ovarian cancer risk. The Copenhagen Index was introduced in 2015, of which the advantage is that it does not depend on ultrasound and menopausal status, while the patient’s age is an objective variable and can be easily collected
RMI 4
In 1990, Jacobs et al. proposed a risk of malignancy index (RMI) by combining the values of CA125, ultrasound, and menopausal status. This algorithm has been used clinically for a long time in three different versions (RMI I, II and III). By 2009 Yamamoto et al. introduced RMI version IV with a cut-off value of 450
ADNEX
ADNEX is the first 'multi-classification' model to help distinguish between benign ovarian tumors and four malignant tumor subtypes: Borderline tumor, Ovarian cancer stage I, Ovarian cancer stage II-IV, Metastatic cancer to the adnexa
